Bill · H.R. 9169· House(119-HR-9169)
PKD Cures Act
- Introduced
- 6/4/2026
- Last activity
- 6/4/2026 — Referred to the House Committee on Energy and Commerce.
- Sponsored by
- Debbie Wasserman Schultz
- Cosponsors
- - 3 - 4
- Introduced
- In Committee
What this bill would do
This bill is called the PKD Cures Act. It focuses on supporting and expanding research for polycystic kidney disease, which affects about 500,000 Americans and costs Medicare billions of dollars annually. The legislation directs the National Institutes of Health to expand and intensify research activities related to this disease. It also requires the creation of a working group to develop a comprehensive roadmap for research and innovation. Finally, this working group must submit a report detailing its findings and recommendations to Congress within 24 months.
Yes· 3 of 5
Does this put more money into medical research?+8
The legislation directly directs the expansion and intensification of NIH research activities regarding polycystic kidney disease.
Does this put more money into scientific research?+8
The bill mandates an expansion of basic, translational, and clinical research activities at the NIH regarding polycystic kidney disease.
Does this make health care easier to get in general?+7
The bill expands National Institutes of Health research and establishes a roadmap for polycystic kidney disease treatments and care, which will improve long-term healthcare outcomes for patients.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Section 3 adding Section 434B: This provision expands and intensifies National Institutes of Health research regarding polycystic kidney disease, including basic, translational, and clinical research. This is positive because it aims to understand genetic mechanisms, identify potential treatments, and evaluate the safety of new therapies for the approximately 500,000 Americans affected by the disease.
-
Section 3 adding Section 434B(b): This provision requires collaboration with other Federal agencies, academic institutions, and private sector stakeholders, as well as support for training programs. This is positive because it helps accelerate the development of treatments and cures while cultivating a workforce of specialized researchers and clinicians.
-
Section 3 adding Section 434C: This provision establishes a working group to develop a comprehensive roadmap for polycystic kidney disease research, innovation, and care. This is positive because it brings together experts and patient advocates to identify research gaps, propose timelines, and integrate new technologies like artificial intelligence and precision medicine.
Potential Negative Impacts for People
- No Negative Impacts Identified: The provided text of the bill does not contain any specific sections or provisions that outline negative consequences or burdens for individuals or groups of people in the United States.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Healthcare
- Increases Research Funding+8Improves Healthcare Access+7
- Education And Technology
- Increases Scientific Research Funding+8
- Demographic And Interest Groups
- Good For People With Disabilities+7
- Governance And Ideology
- Improves Government Transparency+5
- 7/15/2026
- 1 Cosponsor added.
- 7/13/2026
- 1 Cosponsor added.
- 7/9/2026
- 1 Cosponsor added.
- 6/29/2026
- 1 Cosponsor added.
- 6/4/2026
- Referred to the House Committee on Energy and Commerce.
- 3 Cosponsors added.
- Introduced in House
Don BaconRepublican · Nebraska
Emanuel CleaverDemocrat · Missouri
Suzan DelBeneDemocrat · Washington
Sharice DavidsDemocrat · Kansas
Carol MillerRepublican · West Virginia
Jefferson Van DrewRepublican · New Jersey
Joe WilsonRepublican · South Carolina